Decoy Therapeutics Inc.
DCOYHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframeDecoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company. The $2.3M market capitalization puts DCOY squarely in micro-cap range for its industry. It focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that leverages peptide coiled-coils chemistry and physics to design a-helical peptides through computational and ML tools.
Market Cap
$2.3M
Beta
0.64
P/E (TTM)
0.08
P/E (Fwd)
-0.12
EPS (TTM)
$12.24
EPS (Fwd)
$-8.28
ROE
-827.8%
ROA
-73.4%
Cash
$8.3M
Total Debt
$0
Free CF
-$509,881
52W Change
-98.0%
Annual Financials
Cash vs Debt
Where DCOY stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, DCOY finished 76.12% below its 150-day moving average ($4.90) and 80.17% below its 200-day moving average ($5.90). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is DCOY overbought or oversold?
At the October 20, 2026 close, DCOY's RSI(14) was 10.0, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Decoy Therapeutics Inc. reports $8.3M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$510K. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -827.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With a beta below 0.7, Decoy Therapeutics Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Decoy Therapeutics Inc.'s trajectory.